Hepatitis C virus (HCV) is a major global health burden accounting for around 170 million
chronic infections worldwide. Although highly potent direct-acting antiviral drugs to treat …

Hepatitis C virus (HCV) is a positive sense, single-stranded RNA virus in the Flaviviridae
family. It causes acute hepatitis with a high propensity for chronic infection. Chronic HCV …

RNA-binding proteins (RBPs) determine RNA fate from synthesis to decay. Employing two
complementary protocols for covalent UV crosslinking of RBPs to RNA, we describe a …

Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been
developed against this virus. In addition, currently approved pharmacotherapies achieve …

Until recently, the standard of care (SOC) for patients with chronic hepatitis C virus (HCV)
infection has consisted of a combination of pegylated interferon-N1 plus ribavirin …

Since one of us co-authored a review on NS5A a decade ago, the hepatitis C virus (HCV)
field has changed dramatically, primarily due to the advent of the JFH-1 cell culture …

Human papillomaviruses (HPV) are composed of the major and minor capsid proteins, L1
and L2, that encapsidate a chromatinized, circular double-stranded DNA genome. At the …

Cyclophilins (Cyps) belong to the family of peptidyl-prolyl isomerases (PPIases). The PPIase
activity of most Cyps is inhibited by the immunosuppressive drug cyclosporin A and several …

Two classes of hepatitis C antiviral agents currently exist, ie, direct-acting antivirals and host-
targeting antivirals. Direct-acting antivirals target viral proteins including NS3/NS4A …

Cyclophilins (Cyps), characterized as peptidyl-prolyl cis-trans isomerases (PPIases), are
highly conserved and ubiquitous, playing a crucial role in protein folding and cellular …